Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Extensive use of praziquantel for treatment and control of schistosomiasis requires a comprehensive understanding of efficacy and safety of various doses for different Schistosoma species. METHODOLOGY/PRINCIPAL FINDINGS: A systematic review and meta-analysis of comparative and non-comparative trials of praziquantel at any dose for any Schistosoma species assessed within two months post-treatment. Of 273 studies identified, 55 were eligible (19,499 subjects treated with praziquantel, control treatment or placebo). Most studied were in school-aged children (64%), S. mansoni (58%), and the 40 mg/kg dose (56%); 68% of subjects were in Africa. Efficacy was assessed as cure rate (CR, n=17,017) and egg reduction rate (ERR, n=13,007); safety as adverse events (AE) incidence. The WHO-recommended dose of praziquantel 40 mg/kg achieved CRs of 94.7% (95%CI 92.2-98.0) for S. japonicum, 77.1% (68.4-85.1) for S. haematobium, 76.7% (95%CI 71.9-81.2) for S. mansoni, and 63.5% (95%CI 48.2-77.0) for mixed S. haematobium/S. mansoni infections. Using a random-effect meta-analysis regression model, a dose-effect for CR was found up to 40 mg/kg for S. mansoni and 30 mg/kg for S. haematobium. The mean ERR was 95% for S. japonicum, 94.1% for S. haematobium, and 86.3% for S. mansoni. No significant relationship between dose and ERR was detected. Tolerability was assessed in 40 studies (12,435 subjects). On average, 56.9% (95%CI 47.4-67.9) of the subjects receiving praziquantel 40 mg/kg experienced an AE. The incidence of AEs ranged from 2.3% for urticaria to 31.1% for abdominal pain. CONCLUSIONS/SIGNIFICANCE: The large number of subjects allows generalizable conclusions despite the inherent limitations of aggregated-data meta-analyses. The choice of praziquantel dose of 40 mg/kg is justified as a reasonable compromise for all species and ages, although in a proportion of sites efficacy may be lower than expected and age effects could not be fully explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“other drugs, placebo, or comparing different PZQ dosing regimens, risk ratios with 95% confidence intervals (RR, 95%CI), meta-analysis with random effect on the study/site was used and pooled RR presented using the DerSimonian and Laird procedure for random effects models [10].”
MethodAssessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,156 · cited 1×
“Some 779 million people are estimated to live in areas with varying levels of risk of contracting schistosomiasis [1].”
BackgroundKnopp, S., Mohammed, K. A., Speich, B., Hattendorf, J., Khamis, I. S., Khamis, A. N., Stothard, J. R., Rollinson, D., Marti, H., & Utzinger, J. (2010) · Clinical Infectious Diseases · doi:10.1086/657310 · Cited by 172 · cited 1×
“The 95%CI for the mean CR, ERR, AE were calculated using a bootstrap resampling method with a maximum of 1000 replicates [9].”
MethodOlliaro, P., Delgado-Romero, P., & Keiser, J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt491 · Cited by 159 · cited 1×
“This must be due to different species susceptibility, because this happens in spite of exposure to praziquantel increasing overproportionally with the dose (the firstpass-metabolism in the liver being dose-dependent with regard to capacity) [84].”
BackgroundSelf-citationOlds, G. R., King, C., Hewlett, J., Olveda, R., Wu, G., Ouma, J., Peters, P., McGarvey, S., Odhiambo, O., Koech, D., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/314686 · Cited by 156
Drugs for treating urinary schistosomiasis
Kramer, C. V., Zhang, F., Sinclair, D., & Olliaro, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000053.pub3 · Cited by 147 · cited 1×
“The PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement [13] was used as a guide in the reporting of this study.”
MethodSelf-citationKeiser, J., N’Guessan, N. A., Adoubryn, K. D., Silué, K. D., Vounatsou, P., Hatz, C., Utzinger, J., & N'Goran, E. K. (2010) · Clinical Infectious Diseases · doi:10.1086/651682 · Cited by 145
N’GORAN, E. K., Utzinger, J., GNAKA, H. N., YAPI, A., N’Guessan, N. A., Silué, K. D., Lengeler, C., Chollet, J., SHUHUA, X., & Tanner, M. (2003) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2003.68.24 · Cited by 104
Borrmann, S., Szlezák, N., Faucher, J., Matsiegui, P., Neubauer, R., Binder, R. K., Lell, B., & Kremsner, P. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/324004 · Cited by 102
Cited by
McManus, D. P., Dunne, D. W., Sacko, M., Utzinger, J., Vennervald, B. J., & Zhou, X.-N. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0013-8 · Cited by 1,145
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
Broyles, A. D., Banerji, A., Barmettler, S., Biggs, C. M., Blumenthal, K., Brennan, P. J., Breslow, R. G., Brockow, K., Buchheit, K. M., Cahill, K. N., et al. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.08.006 · Cited by 235
Crellen, T., Walker, M., Lamberton, P. H. L., Kabatereine, N. B., Tukahebwa, E. M., Cotton, J. A., & Webster, J. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw506 · Cited by 208
“mansoni infections in schoolchildren, with a median follow-up time of 5 weeks [28].”
Background(2025) · doi:10.1073/pnas.2505710122 · Cited by 8
Metadata
- Authors
- Zwang, J., & Olliaro, P. L.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-11-20
- Volume
- 8
- Issue
- 11
- Pages
- e3286
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W1973652786
- Cited by
- 185
- References
- 28
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials. https://app.cochat.ai/papers/10.1371/journal.pntd.0003286
- The paper
- Zwang, J., & Olliaro, P. L. (2014). Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials. PLoS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0003286
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.